Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs McKesson Corporation (MCK) Price & Performance

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs McKesson Corporation — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.29 (market cap $40.01B), while McKesson Corporation trades at $936.09 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 2.7× Haleon plc American Depositary Shares (Each representing two Ordinary Shares)'s market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and McKesson Corporation for 74 Days on average.

HLNMCK
Market Cap
$40.01B$108.46B
Volume
19,985,935712,607
Sector
HealthHealth
52-Week High
$11.27$995.69
52-Week Low
$8.70$725.17
Typical Hold Time
0 Days74 Days
Enterprise Value
$49.79B$115.00B
Dividend Yield
2.14%0.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

No Aura AI signal available yet.

McKesson Corporation

McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.

The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLN
100% Buy0% Sell
Avg holding period · 0 Days
MCK
40% Buy60% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →